Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01701817 · ClinicalTrials.gov registry record
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
A clinical trial, sponsored by Janssen Scientific Affairs.
- Completed
- Registry status
- 13,769
- Enrollment target
NCT01701817 is a clinical trial that has completed, run by Janssen Scientific Affairs. The registered enrollment target is 13,769 participants.
The verdict
NCT01701817 has completed, sponsored by Janssen Scientific Affairs.
- COMPLETED
- Registry status
- 13,769 participants
- Enrollment target
Study Summary
The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF II) is a multicenter, prospective outpatient disease registry to evaluate the utilization of target-specific antithrombotic agents, such as FXa (factor Xa) inhibitors and direct thrombin inhibitors, and associated outcomes. Importantly, the ORBIT AF II registry will permit the collection and analysis of post-approval observational data needed for evaluating the outcomes associated with these new agents when used in broader patient populations outside of clinical studies. The ORBIT-AF II registry will focus on patients with newly diagnosed atrial fibrillation (AF) as well as those who have been recently started on a target-specific oral anticoagulant agent. Taken together, the ORBIT-AF I and ORBIT-AF II registries will offer a broad and contemporary view of AF therapy.
Interventions
- OTHER Patients with Atrial Fibrillation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,769 participants |
| Start Date | 2013-02-20 |
| Est. Completion | 2017-07-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01701817
The ClinicalTrials.gov registry entry for NCT01701817 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 13,769 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Scientific Affairs, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Patients with Atrial Fibrillation is the first listed.
NCT01701817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01701817 about?
NCT01701817 is a clinical study titled "Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)". The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF II) is a multicenter, prospective outpatient disease registry to evaluate the utilization of target-specific antithrombotic agents, such as FXa (factor Xa) inhibitors and direct thrombin inhibitors, and associated o...
What is the current status of trial NCT01701817?
This trial is currently completed. The enrollment target is 13,769 participants. The study started on 2013-02-20. Estimated completion is 2017-07-12.
What interventions are being tested in trial NCT01701817?
The interventions under investigation include: Patients with Atrial Fibrillation (OTHER).
Who is sponsoring clinical trial NCT01701817?
This trial is sponsored by Janssen Scientific Affairs, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.